Florzolotau
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT03058965)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Microtubule-associated protein tauRadiopharmaceutical
MAPT radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
CNc1ccc(/C=C/C=C/c2nc3ccc(OCC(O)CF)cc3s2)cn1- Mol. weight
- 385.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095503 ↗
Also known as
- mni-958
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03545789 | Phase 1 | Mar 12, 2018 | Invicro |
| NCT03472313 | Phase 1 | Nov 14, 2017 | Invicro |
| NCT03058965 | Early Phase 1 (Phase 1) | Nov 1, 2016 | Molecular NeuroImaging |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Invicro | For profit | 2 | 2 | 1 | 2017 |
| Molecular NeuroImaging | For profit | 1 | 1 | 1 | 2016 |
2 organizations
Page 1 / 1